Search results for: Precision Medicine
Filter search results
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
…the new class of innovative medicines. Next, we modelled the life-cycle uptake of risperidone to estimate the life-cycle incremental cost (i.e., direct, indirect and medicine costs), incremental QALYs and Net…
OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare
15 June 2020
…world, medicines reimbursement decisions are based on health technology assessments (HTA) applying cost-effectiveness criteria. Some HTA bodies use a CET as a rule for such decisions. A recent OHE report opens the…
Indication-Based Pricing (IBP) Consultation Report
1 April 2020
Although the science underlying drug development has evolved, there has been little change in how we pay for them. As more and more medicines come to market with multiple indications…
Multi-Criteria Decision Analysis to Value Orphan Medicines
1 May 2013
…Sussex, J., Rollet, P., Garau, M., Schmitt, C., Kent, A. and Hutchings, A., 2013. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value in Health, 16(8), pp.1163-1169….
Impact of New Medicines on Health Care Costs
1 March 1989
…referred to in the Box on page 2. This Briefing, however, refers only to health service costs and to the direct savings which medicines can yield within the Health Service….
Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe
1 October 2010
…Member States and its impact on patients’ access to medicines Consider how EFPIA could develop responses to these findings to engage in constructive dialogue around the scientific merit and public…
Economic Aspects of the Development of New Medicines
1 January 1981
…challenged by critics such as McKeown (1976); but again it would require another lecture to answer such criticisms. Finally, I have omitted the important role of medicines in animal health….
Costs and Benefits of Regulating New Product Development in the UK Pharmaceutical Industry
3 January 1982
…new medicines. Indeed Hartley and Maynard go so far as to discuss the possibility of a return to a voluntary scheme for the approval of new medicines, such as operated…
OHE Study on Pharmaceutical R&D Costs Released
3 December 2012
How much it costs to research and develop a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter not just because of…